Such models are “two-stage” because even if we utilize the current AD models as the “first-stage,” express iAβ42, or elicit the ISR independently of iAβ to enable the “second-stage,” we still have to introduce transgenes expressing human AβPP mRNA eligible for the amplification process. The gene discussed is APP; the disease is Alzheimer disease.